Assessing tumor signatures in glioblastoma patients after autopsy
NovoTTF Treatment Signatures in Glioblastoma Patients At Autopsy
This study is trying to see how tumors in glioblastoma patients who received a special treatment called TTFields compare to those who didn’t, by looking at brain samples after they pass away.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Medical College of Wisconsin Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Milwaukee, Wisconsin) |
| Trial ID | NCT03194971 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze whole brain samples from glioblastoma patients who have undergone Optune therapy with tumor treatment fields (TTFields) at autopsy. The goal is to identify the pathological signatures of tumors treated with TTFields compared to those that have not received this treatment. By enrolling patients with newly diagnosed and recurrent glioblastoma, the study will compare the patterns of tumor failure between these two groups. The investigators plan to enroll a total of 20 patients over four years to achieve this objective.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with newly diagnosed or recurrent glioblastoma who are undergoing TTField therapy.
Not a fit: Patients who do not comply with TTField treatment or have contraindications to Optune therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into the effectiveness of TTFields in treating glioblastoma and inform future treatment strategies.
How similar studies have performed: While TTFields have shown promise in clinical trials, this specific approach of assessing tumor signatures at autopsy is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Newly diagnosed glioblastoma, World Health Organization (WHO) grade IV, patients undergoing TTField therapy. * Recurrent glioblastoma WHO grade IV, patients undergoing TTField therapy. Exclusion Criteria: * TTField compliance \< 75%. * Any contraindication to Optune TTField treatment. * Initial brain tumor diagnosis \< WHO grade IV. * Duration of TTField therapy \< 3 months.
Where this trial is running
Milwaukee, Wisconsin
- Froedtert & the Medical College of Wisconsin — Milwaukee, Wisconsin, United States (Recruiting)
Study contacts
- Principal investigator: Peter LaViolette, PhD — Medical College of Wisconsin
- Study coordinator: Medical College of Wisconsin Cancer Center Clinical Trials Office
- Email: cccto@mcw.edu
- Phone: 414-805-8900
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.